The landmark 2017 National Academies report — the most rigorous evidence review to date — found substantial evidence for only three indications: chronic pain in adults, chemotherapy-induced nausea (oral cannabinoids), and MS-related spasticity. Nearly everything else sits at "limited" or "insufficient."